Rna Diagnostics selected to participate in EXCITE program to evaluate RDA™

By |May 30th, 2013|

TORONTO, Ontario

Rna Diagnostics, Inc. (RnaDx) has been accepted into the MaRS Excellence in Clinical Innovation and Technology Evaluation (EXCITE) program for the clinical evaluation of their diagnostic test, RNA Disruption Assay™ (RDA™),and its impact on patient care for individuals undergoing breast cancer chemotherapy. Through EXCITE, […]

Cancer Research Aimed at Improving Treatment

By |April 15th, 2013|

A diagnostic test intended to improve treatment of human breast cancer is now under investigation by University of Guelph researchers for potential use in dogs with lymphoma. Prof. Brenda Coomber, Biomedical Sciences, leads researchers in the Ontario Veterinary College (OVC) in a new study meant to […]

First Real Time Breast Cancer Chemotherapy Guidance Tool

By |March 11th, 2013|

Rna Diagnostics says its RNA Disruption Assay (RDA) will save. It will save patients and it will save money.
The RDA is a test that allows doctors to know with 99 per cent certainty after one to two cycles whether a patient with breast cancer will achieve […]

Mitacs-Accelerate Intern kicks off her career by helping to commercialize a breast cancer treatment tool

By |February 26th, 2013|

Chemotherapy has long been used to treat people with cancer, but its effectiveness varies greatly from patient to patient.  For example, when used to treat breast cancer, fewer than 40% of patients respond positively.

However, it is difficult for doctors to determine which patients are not […]

Rna Diagnostics Receives Federal Government Funding for Breast Cancer Technology

By |February 19th, 2013|

TORONTO, Ontario
Rna Diagnostics (RnaDx) received $462,500 today from the Federal Economic Development Agency for Southern Ontario (FedDev Ontario).

Through FedDev Ontario’s Investing in Business Innovation initiative, Rna Diagnostics Inc. will receive a repayable contribution of up to $462,500 to prepare their diagnostic test, RNA Disruption Assay™ (RDA™), […]

Rna Diagnostics – A Success Story

By |January 28th, 2013|

Funding from the Northern Ontario Heritage Fund Corporation (NOHFC) helped Rna Diagnostics develop a new test that will guide chemotherapy treatment for cancer patients. More on this success story.

Paul Lucas joins Rna Diagnostics’ Business Advisory Board

By |December 14th, 2012|

TORONTO, Ontario
Dr. Ken Pritzker, President and CEO of Rna Diagnostics, is pleased to announce that Paul Lucas has joined the business advisory board of Rna Diagnostics.  Mr. Lucas is an accomplished member of Canada’s pharmaceutical community and a strong advocate for commercialization of Canadian diagnostics […]

Rna Diagnostics featured on CTV

By |December 11th, 2012|

Dr. Amadeo Parissenti, Chief Scientific Officer of Rna Diagnostics was featured on CTV News in Sudbury. The two-minute clip featured an interview with Dr. Parissenti in Rna Diagnostics’ laboratory in Sudbury. To preview the clip, contact John Jordan, Rna Diagnostics at jjordan@rnadiagnostics.com.

Improving the management and treatment of breast cancer

By |November 27th, 2012|

Rna Diagnostics is featured in The Health Technology Exchange’s 2011-2012 Annual Report. See pages 28,29.

Confronting Cancer Part 4 – CBC feature, September 4, 2012

By |November 23rd, 2012|

CBC featured an interview with Dr. Amadeo Parissenti describing his research on RNA Disruption Assay™ at the Rna Diagnostics’ Laboratory in Sudbury, Ontario. The interview can be heard by going to the CBC website. Dr. Parissenti’s interview begins at minute 5:08.